ProAxsis assays selected for 1,000-patient respiratory trial.
M2 EQUITYBITES-September 20, 2018-ProAxsis assays selected for 1,000-patient respiratory trial
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Healthcare technology group NetScientific plc (AIM:NSCI) reported on Thursday that its portfolio company ProAxsis Ltd has had two products selected for inclusion in a major upcoming clinical trial funded by the European Respiratory Society (ERS).
The BRIDGE study will use the ProteaseTag Active NE Immunoassay and NEATstik, a test that enables measurement of active neutrophil elastase at point-of-care.
Over three years, 1,000 patients with bronchiectasis will have multiple assessments including microbiome, proteomics, detailed phenotyping and imaging, in order to explore new biomarkers and determine their impact on clinical outcomes.
Bronchiectasis is a long-term condition in which the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection, according to the NHS.
NetScientific has a 54% shareholding in ProAxsis.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Sep 20, 2018|
|Previous Article:||Genuine Parts to Acquire Hydraulic Supply Company, Hastings Auto Parts.|
|Next Article:||Celgene drops option on OncoMed's navicixizumab.|